LIF 247Alternative Names: LI 247
Latest Information Update: 17 Dec 2007
At a glance
- Originator Enhance Lifesciences
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Major depressive disorder
Most Recent Events
- 19 Nov 2003 Phase-III clinical trials in Depression in USA (unspecified route)